| Literature DB >> 33925485 |
Theresa Hermann1, Patrick Hochegger1, Johanna Dolensky1, Werner Seebacher1, Robert Saf2, Marcel Kaiser3, Pascal Mäser3, Robert Weis1.
Abstract
An N-acylated furazan-3-amine of a Medicines for Malaria Venture (MMV) project has shown activity against different strains of Plasmodium falciparum. Seventeen new derivatives were prepared and tested in vitro for their activities against blood stages of two strains of Plasmodium falciparum. Several structure-activity relationships were revealed. The activity strongly depended on the nature of the acyl moiety. Only benzamides showed promising activity. The substitution pattern of their phenyl ring affected the activity and the cytotoxicity of compounds. In addition, physicochemical parameters were calculated (log P, log D, ligand efficiency) or determined experimentally (permeability) via a PAMPA. The N-(4-(3,4-diethoxyphenyl)-1,2,5-oxadiazol-3-yl)-3-(trifluoromethyl)benzamide possessed good physicochemical properties and showed high antiplasmodial activity against a chloroquine-sensitive strain (IC50(NF54) = 0.019 µM) and even higher antiplasmodial activity against a multiresistant strain (IC50(K1) = 0.007 µM). Compared to the MMV compound, the permeability and the activity against the multiresistant strain were improved.Entities:
Keywords: PAMPA; Plasmodium falciparum; antimalarial; furazan derivatives
Year: 2021 PMID: 33925485 DOI: 10.3390/ph14050412
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247